-
NBA fines 76ers' Drummond, Magic's Suggs $25,000 each
-
Switzerland's Ehammer sets indoor heptathlon world record
-
Pogacar 'relieved' by Milan-San Remo triumph, gunning to complete Monument set
-
World Athletics decision to hand Asia two world indoors 'strategic' - Coe
-
Trump threatens to use ICE agents for airport security control
-
Kane moves closer to goals record as Bayern sink Union
-
Pogacar ends long wait for Milan-San Remo glory after edging epic
-
US says 'took out' Iran base threatening blocked Hormuz oil route
-
Di Giannantonio takes Brazil MotoGP pole ahead of Bezzecchi, Marquez
-
Welbeck scores twice to dent Liverpool's top-five hopes
-
US strikes Iran bases threatening blocked Hormuz oil route
-
Pirovano wins World Cup downhill title, Aicher puts pressure on Shiffrin
-
Doroshchuk wins Ukraine's second world indoor gold, Hodgkinson and Alfred coast
-
K-pop kings BTS stun Seoul in '2.0' comeback concert
-
French prosecutors suspect Musk encouraged deepfakes row to inflate X value
-
Mbappe 100 percent, Bellingham fit, says Real Madrid's Arbeloa
-
Iranians mark Eid as Tehran reports strike on nuclear plant
-
Kenya, Uganda open rail extension burdened by Chinese debt
-
K-pop kings BTS rock Seoul in comeback concert
-
Invincible Japan edge Australia to win Women's Asian Cup
-
Italy's Paris claims first win of season in World Cup downhill finale
-
In Finland, divers learn to explore icy polar waters
-
Dortmund extend injured captain Can's contract
-
Iranians mark Eid as Trump mulls winding down war
-
Matisse's last years cut out -- but not pasted -- at Paris expo
-
BTS fans take over central Seoul for K-pop kings' comeback
-
Star jockey McDonald becomes horse racing's most prolific Group 1 winner
-
Israel strikes Tehran, Beirut as Trump mulls 'winding down' war
-
Pistons top Warriors to clinch NBA playoff berth
-
Tickets to toothbrushes: BTS's money-making machine
-
Top-ranked Alcaraz, Sabalenka win Miami openers
-
After Cuba beckons, Miami entrepreneurs are mostly reluctant to invest in the island
-
Peru's crowded presidential race zeroes in on organized crime
-
Taiwan's Lin to compete in first international event since Paris gender row
-
BTS takes over central Seoul for comeback concert
-
Jury signals tech titans on hook for social media addiction
-
Brumbies mark Slipper record in thriller against Chiefs
-
US jury finds Elon Musk misled Twitter shareholders
-
Gauff rallies to avance at Miami Open
-
WNBA, players union confirm agreement on 'groundbreaking' labor deal
-
Carrick 'baffled' by inconsistent penalty calls as Man Utd held
-
Trump says considering 'winding down' Iran war but rules out ceasefire
-
Trump mulls 'winding down' Iran war
-
Man Utd held by Bournemouth after Maguire sees red
-
Lens go top of Ligue 1 with handsome Angers win
-
Leipzig pummel Hoffenheim to climb to third
-
Quinn ousts 11th seed Ruud at rain-hit Miami Open
-
Rap group Kneecap says crisis-hit Cuba being 'strangled'
-
Anthony, Jackson nail US double at world indoors
-
Zarco seizes his moment as rain disrupts Brazil MotoGP practice
US panel weighs authorizing Covid vaccines for youngest children
After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.
Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.
Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."
Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.
Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.
They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.
But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.
There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.
Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.
Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."
E.Raimundo--PC